{"id":702960,"date":"2024-06-17T17:48:02","date_gmt":"2024-06-17T17:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=702960"},"modified":"2024-06-17T17:48:02","modified_gmt":"2024-06-17T17:48:02","slug":"acute-graftversushost-disease-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals-drugs-and-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-graftversushost-disease-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals-drugs-and-companies_702960.html","title":{"rendered":"Acute Graft-Versus-Host Disease Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1718618033.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acute Graft-Versus-Host Disease Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1718618033.jpeg\" alt=\"Acute Graft-Versus-Host Disease Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;Acute Graft-versus-Host Disease Pipeline Insight, 2024,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about&nbsp;<strong>21+ companies and 23+ pipeline drugs<\/strong>&nbsp;in Acute Graft-versus-Host Disease pipeline landscape. It covers the Acute Graft-Versus-Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Graft-Versus-Host Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Explore our latest breakthroughs in Acute Graft-Versus-Host Disease research. Learn more about our innovative pipeline today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Acute Graft-Versus-Host Disease Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Acute Graft-Versus-Host Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><em><strong>June 2024:- Equillium-<\/strong><\/em> A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease. This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids.<\/li>\n<li><em><strong>June 2024:-Institut de Recherches Internationales Servier-<\/strong> <\/em>Phase I \/ II, Open Label, Dose Escalation Part (Phase I) Followed by Non-comparative Expansion Part (Phase II), Multi-centre Study, Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a Bcl2 Inhibitor Combined With Azacitidine in Adult Patients With Previously Untreated Acute Myeloid Leukemia Not Eligible for Intensive Treatment.<\/li>\n<li><em><strong>June 2024:- M.D. Anderson Cancer Center<\/strong><\/em>&#8211; A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine\/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE). Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine\/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL).<\/li>\n<li><em><strong>June 2024:- Novartis Pharmaceuticals<\/strong><\/em>&#8211; The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (&ge;70 mg\/dL) despite being treated with a statin drug,<\/li>\n<li>DelveInsight&rsquo;s Acute Graft-Versus-Host Disease pipeline report depicts a robust space with 21+ active players working to develop 23+ pipeline therapies for Acute Graft-Versus-Host Disease treatment.<\/li>\n<li>The leading Acute Graft-Versus-Host Disease Companies such as<em><strong> MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, Incyte Corporation,<\/strong><\/em> and others.<\/li>\n<li>Promising Acute Graft-Versus-Host Disease Therapies such as <em><strong>Uvadex, ASC930, Jaktinib Hydrochloride Tablets, EQ001<\/strong><\/em>, Abatacept, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Stay informed about the cutting-edge advancements in Acute Graft-Versus-Host Disease treatments. Download for updates and be a part of the revolution in cancer care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Acute Graft-Versus-Host Disease Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Acute Graft-Versus-Host Disease Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>MaaT013: MaaT Pharma<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">MaaT Pharma is developing MaaT013, which is made up of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota manufactured in France, per the GMP requirements. It is an off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic in enema formulation. The product is characterized by a high diversity and consistent richness of microbial species. MaaT013 aims to restore the symbiotic relationship between the patient&rsquo;s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. The drug is currently being evaluated under Phase III clinical trial for the treatment of Acute Graft-versus-Host Disease.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Lenzilumab: Humanigen<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Lenzilumab is a proprietary Humaneered first-in-class monoclonal antibody that has been proven to neutralize GM-CSF, a cytokine of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome, or cytokine storm, associated with COVID-19 and other indications. Lenzilumab binds to and neutralizes GM-CSF, consequently improving outcomes for patients hospitalized with COVID-19. Humanigen believes that its GM-CSF neutralization has the potential to reduce the hyper-inflammatory cascade known as cytokine release syndrome common to chimeric antigen receptor T-cell (CAR-T) therapy and aGvHD. The drug is currently being evaluated under Phase II\/III clinical trial for the treatment of Acute Graft-versus-Host Disease.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Apraglutide: Ironwood Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Apraglutide is an investigational new drug that is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD). The drug is currently being evaluated under Phase II clinical trial for the treatment of Acute Graft-Versus-Host Disease (aGVHD).<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about Acute Graft-Versus-Host Disease Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Acute Graft-Versus-Host Disease Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Graft-versus-Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Oral<\/li>\n<li>Intramuscular<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Acute Graft-Versus-Host Disease Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal antibody<\/li>\n<li>Small molecule<\/li>\n<li>Peptide<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the latest advancements in Acute Graft-Versus-Host Disease treatment by visiting our website. Stay informed about how we&#8217;re transforming the future of Immunological and Autoimmune Disorders @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Acute Graft-Versus-Host Disease Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Acute Graft-Versus-Host Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Acute Graft-Versus-Host Disease Companies- MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, Incyte Corporation, and others.<\/li>\n<li>Acute Graft-Versus-Host Disease Therapies- Uvadex, ASC930, Jaktinib Hydrochloride Tablets, EQ001, Abatacept, and others.<\/li>\n<li>Acute Graft-Versus-Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Acute Graft-Versus-Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For a detailed overview of our latest research findings and future plans, read the full details of Acute Graft-Versus-Host Disease pipeline on our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Acute Graft-Versus-Host Disease Emerging Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Acute Graft-versus-Host Disease: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Acute Graft-versus-Host Disease&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>MaaT013: MaaT Pharma<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Apraglutide: Ironwood Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Acute Graft-versus-Host Disease Key Companies<\/li>\n<li>Acute Graft-versus-Host Disease Key Products<\/li>\n<li>Acute Graft-versus-Host Disease- Unmet Needs<\/li>\n<li>Acute Graft-versus-Host Disease- Market Drivers and Barriers<\/li>\n<li>Acute Graft-versus-Host Disease- Future Perspectives and Conclusion<\/li>\n<li>Acute Graft-versus-Host Disease Analyst Views<\/li>\n<li>Acute Graft-versus-Host Disease Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acute-graftversushost-disease-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals-drugs-and-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acute-graftversushost-disease-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals-drugs-and-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s,&nbsp;&ldquo;Acute Graft-versus-Host Disease Pipeline Insight, 2024,&rdquo;&nbsp;report provides comprehensive insights about&nbsp;21+ companies and 23+ pipeline drugs&nbsp;in Acute Graft-versus-Host Disease pipeline landscape. It covers the Acute Graft-Versus-Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acute-graftversushost-disease-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals-drugs-and-companies_702960.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-702960","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/702960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=702960"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/702960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=702960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=702960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=702960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}